Triple-negative breast carcinoma

This trial is testing an experimental therapy called IOV-5001, which uses a patient's own immune cells (tumor-infiltrating lymphocytes) to attack cancer. The study involves adults with advanced solid tumors, including non-small cell lung cancer, triple-negative breast cancer, col…

This phase 1 trial is testing whether combining the experimental drug zotatifin with the chemotherapy carboplatin can help people with advanced triple-negative breast cancer (TNBC) that has not responded to standard treatments. The study aims to find the safest and most effective…

This early-phase trial is testing whether a personalized cancer vaccine, made from a patient's own tumor, can safely boost the immune system's ability to fight triple negative breast cancer. About 30 newly diagnosed patients will receive the vaccine along with standard chemothera…

This phase III trial is testing whether a new drug called BL-B01D1, combined with an immunotherapy (PD-1 antibody), works better than standard chemotherapy plus immunotherapy for people with advanced triple-negative breast cancer that has a specific protein (PD-L1). The study inc…

This phase II trial is testing whether combining two drugs—sacituzumab govitecan, an antibody-drug conjugate that delivers chemotherapy directly to cancer cells, and Q901, a targeted drug that blocks a key enzyme cancer cells need to divide—can shrink tumors in people with advanc…

This trial is testing whether giving a combination of immunotherapy (pembrolizumab) and chemotherapy before surgery can shrink or eliminate tumors in people with stage I triple-negative breast cancer. The study compares different treatment regimens to see which is most effective …

This early-phase trial is testing a personalized cancer vaccine called BreakVax, designed from each patient's own tumor, in combination with immunotherapy and chemotherapy for advanced triple-negative breast cancer. The goal is to see if this multi-pronged approach can safely boo…

This phase III trial is testing whether adding everolimus to trastuzumab rezetecan helps people with a specific subtype of triple-negative breast cancer (called luminal androgen receptor) live longer without their disease progressing. The study enrolls adults with advanced or met…

This trial is testing an experimental therapy called CRG-150, which uses a patient's own immune cells that have been gene-edited to potentially fight cancer. The study includes adults with advanced HR-positive/HER2-negative breast cancer, triple-negative breast cancer, or prostat…

This phase 2 trial is investigating whether adding an experimental drug called retlirafusp alfa to standard chemotherapy or to another drug called fuzuloparib can improve outcomes for people with triple-negative breast cancer (TNBC). The study includes two groups: one with early-…

This phase 3 trial tests whether a combination of sacituzumab govitecan (Trodelvy) and pembrolizumab (Keytruda) works better than standard chemotherapy before surgery for stage II-III triple-negative breast cancer. About 765 participants will be enrolled. The study aims to improv…

This Phase II trial will test whether adding a live biotherapeutic product called MO-03 (a type of probiotic) to standard chemotherapy and the immunotherapy drug pembrolizumab can improve outcomes for 50 people with early-stage triple-negative breast cancer. Participants will tak…

This phase 2 trial is testing whether adding an investigational drug called ivonescimab to standard chemotherapy before surgery can improve outcomes for people with triple-negative breast cancer. Ivonescimab is a bispecific antibody that works in two ways: it helps the immune sys…

This phase 2 trial tests whether alternating two targeted chemotherapy drugs—sacituzumab govitecan and trastuzumab deruxtecan—can help people with HER2-low triple-negative breast cancer that has spread. About 260 participants will be randomly assigned to receive either the altern…

This trial is testing an experimental drug called GB268, a tri-specific antibody that targets three key pathways involved in cancer growth. It is being studied alone or in combination with other treatments in people with locally advanced or metastatic breast cancer. The goal is t…

This study tests a drug called sacituzumab tirumotecan in 20 people with triple-negative breast cancer that has spread to the brain. The drug is given through a vein twice a month. The main goal is to see if it can shrink brain tumors. This is an early-phase trial, so it focuses …

This phase II trial is testing whether a vaccine called STEMVAC can help prevent triple-negative breast cancer from coming back after surgery. The vaccine targets proteins that cancer cells use to grow and spread, aiming to boost the immune system to destroy any remaining tumor c…

This phase 3 trial tests whether a single dose of SRG-514 (ketorolac), given directly into the area where a breast tumor is removed, can help prevent cancer from coming back. The study enrolls adults with stage II-III triple-negative breast cancer who are having breast-conserving…

This study investigates whether adding isunakinra, a modified protein that blocks inflammation, can make triple-negative breast cancer more sensitive to standard immunotherapy and chemotherapy. The trial enrolls adults with newly diagnosed, locally advanced triple-negative breast…

This study tests a combination of three drugs—tislelizumab, bevacizumab, and capecitabine—in people with advanced solid tumors. The trial focuses on two challenging groups: those whose cancers have stopped responding to immunotherapy and those with tumors that have spread to the …

This pilot study tests whether adding a device called TheraBionic P1 to standard treatment can help women with metastatic triple negative breast cancer who have already tried two prior treatments. The device delivers low-level radiofrequency electromagnetic fields and is used alo…

This phase 3 trial is testing a drug called trastuzumab rezetecan, alone or combined with bevacizumab, in 140 women with advanced triple-negative breast cancer that has a specific immune-suppressed pattern. The goal is to see if the combination can delay cancer growth better than…

This early-phase trial tests an oral drug called Zn-Telomir in 76 adults with advanced or metastatic triple-negative breast cancer that has worsened after prior treatments. The study has two parts: first, finding a safe dose, and second, checking if the drug shrinks tumors. It is…

This study is testing whether some people with early-stage breast cancer can safely skip surgery after chemotherapy and instead use only radiation. It includes 84 adults with HER2-positive or triple-negative breast cancer who have responded well to initial chemo. The goal is to s…

This study tests a new drug (GV20-0251) combined with an immunotherapy (anti-PD-1) in people with advanced solid tumors that have not responded to or cannot tolerate standard treatments. About 227 adults with various cancers, including lung, breast, and colorectal, will participa…

This study tests whether a new drug, sacituzumab tirumotecan (Sac-TMT), followed by standard chemotherapy (capecitabine), works better than capecitabine alone to keep early-stage, high-risk triple-negative breast cancer from returning. About 420 women without BRCA gene mutations …

This study looks at whether women with triple-negative breast cancer who have a complete response to chemo-immunotherapy can safely skip breast and lymph node surgery. Half of the 150 participants will receive standard care including surgery, while the other half will have no sur…

This phase 3 trial compares a new drug called 9MW2821 to standard chemotherapy in 356 people with advanced triple-negative breast cancer who have already received certain prior treatments. The main goal is to see if the new drug helps people live longer. Participants will receive…

This phase 2 trial tests whether adding a targeted drug (axatilimab) and radiation to the immunotherapy pembrolizumab can help shrink tumors in people with metastatic triple-negative breast cancer who have already tried immunotherapy. About 34 participants will receive all three …

This study compares two chemotherapy drugs—gemcitabine and paclitaxel—in Black Caribbean women with metastatic triple-negative breast cancer. The goal is to see if gemcitabine, usually used later, works better as a first treatment. 750 women from Jamaica, Trinidad, and Barbados w…

This study is for people with advanced triple negative breast cancer, a type that is harder to treat. It tests a new oral liquid drug called BLEX 404 given with the chemotherapy drug Docetaxel. The goal is to find a safe dose and see if the combination helps shrink tumors. About …

This study tests a new drug, QLC5513, alone or with another drug (QL1706) in 60 women with advanced triple-negative breast cancer that has worsened after at least one prior treatment. The goal is to see if these drugs can shrink tumors or slow the cancer's growth. Participants wi…

This study tests whether adding the immunotherapy drug camrelizumab to chemotherapy and radiation before surgery can eliminate all signs of early-stage triple-negative breast cancer. About 43 women with newly diagnosed, untreated disease will receive the combination for 12 weeks,…

This Phase 2 trial tests a new drug called HLX43, which is designed to seek out and destroy cancer cells in people with advanced triple-negative breast cancer (TNBC). The study will test HLX43 alone or combined with other immune-boosting drugs. About 180 adults with TNBC that has…

This study tests whether adding the immunotherapy drug pembrolizumab to usual post-surgery treatment can help prevent breast cancer from returning in people with early-stage triple-negative breast cancer who still had cancer after initial chemo and pembrolizumab. About 1,000 adul…

This phase 2 trial will test a combination of two drugs—serplulimab (an immunotherapy) and SHR-A1811 (a targeted chemotherapy)—given before surgery to women with early-stage triple-negative breast cancer. The main goal is to see how many patients have no cancer left at the time o…

This phase 2 trial tests whether injecting the anesthetic levobupivacaine around the tumor and nearby nerves during breast cancer surgery can reduce the risk of the cancer returning. The study will include 760 women with triple-negative breast cancer who have had chemotherapy and…

This study tests a combination of two drugs, inavolisib and eribulin, in people with advanced triple-negative breast cancer that has a PIK3CA mutation and has not responded to at least one prior treatment. The goal is to see if the combination shrinks tumors and is safe. About 26…

This early-phase trial tests an experimental drug called ITC-6146RO in about 102 adults with advanced or metastatic cancers (like prostate, lung, or breast cancer) that have not improved with standard treatments. The study has two parts: first, finding a safe dose, then checking …

This study tests whether a three-drug combination can help people with triple-negative breast cancer whose tumors stopped responding to immunotherapy. About 46 women will receive cromolyn, TQB2102, and panpulimab to see if tumors shrink or stop growing. The goal is to control the…

This Phase 2 trial tests whether adding the experimental drug QL1706 to standard platinum chemotherapy helps people with advanced triple negative breast cancer live longer without their disease getting worse. About 78 adults who have already had one or two prior treatments will b…

This study tests whether taking the oral drug everolimus after standard chemotherapy can help prevent breast cancer from coming back in people with a specific subtype of triple-negative breast cancer called LAR. The trial will enroll 904 women who have had surgery for early-stage…

This Phase 2 trial tests a new antibody drug (QL1706) combined with chemotherapy in 40 people with early triple-negative breast cancer. The treatment is tailored based on how the tumor responds after initial cycles, with the goal of avoiding certain heart-damaging drugs if possib…

This study looks at two powerful drugs, sacituzumab govitecan (SG) and trastuzumab deruxtecan (T-DXd), for people with a certain type of advanced breast cancer (HER2-low/TROP2-high). The goal is to find out which drug works best when given first and how to switch if the first sto…

This phase 2 trial is testing the drug sacituzumab govitecan (Trodelvy) as a first treatment for people with advanced triple-negative breast cancer who haven't had prior therapy for advanced disease. Researchers want to see if the drug can shrink tumors or slow the cancer's growt…

This early-stage trial tests whether fecal microbiota transplants (FMT) from healthy donors can safely be added to standard chemotherapy and immunotherapy for triple-negative breast cancer. About 125 patients will take part, first in an observation phase and then in a treatment p…

This study tests whether adding a targeted drug (olaparib) to a standard chemotherapy (temozolomide) can better control advanced triple-negative breast cancer that has a specific genetic marker (MGMT methylation). About 40 adults with this cancer type will be randomly assigned to…

This phase II trial is testing whether a combination of two drugs—sacituzumab govitecan (a targeted chemotherapy) and tislelizumab (an immunotherapy)—can effectively treat early-stage triple-negative breast cancer with a less intense approach. The study will enroll 30 people and …

This phase 2 trial tests the drug olaparib in 30 women with recurrent or metastatic triple-negative breast cancer that has a specific DNA change (BRCA1 promoter methylation) but no BRCA gene mutation. Participants take olaparib pills until the disease worsens or side effects beco…

This Phase 2 trial tests whether adding the immunotherapy drug toripalimab to chemotherapy before surgery can improve outcomes for people with triple-negative breast cancer. About 216 participants will receive either toripalimab plus one of two chemotherapy regimens. The main goa…

This phase 2 trial tests whether adding trilaciclib to the chemotherapy drug eribulin can protect bone marrow in people with advanced triple-negative breast cancer who have already tried at least two chemotherapies. The study will enroll 29 participants and measure how often seve…

This phase 2 trial tests a combination of two drugs—Sacituzumab Tirumotecan and Toripalimab—as a first treatment for people with a specific type of advanced triple-negative breast cancer that is PD-L1 positive. The study aims to see if the combo shrinks tumors and improves surviv…

This phase 2 trial tests a combination of two drugs—sacituzumab tirumotecan and pembrolizumab—given before surgery to people with stage II or III triple-negative breast cancer. The goal is to see if the treatment can completely eliminate the cancer by the time of surgery. The stu…

This study is testing whether adding a probiotic called Lactobacillus johnsonii to standard chemotherapy and immunotherapy can help control advanced lung, breast, or stomach cancers. About 156 adults aged 18-75 will be randomly assigned to receive either the probiotic or a placeb…

This early study tests a combination of two immunotherapy drugs (iparomlimab and tuvonralimab), a targeted therapy (olaparib), and chemotherapy (paclitaxel) given before surgery to 20 women with early, high-risk triple negative breast cancer that has a specific DNA repair defect …

This study tests a new drug called SC-101 in 120 people with advanced breast cancer (triple-negative or hormone-receptor-positive) that has a specific gene change called NECTIN4 amplification. Participants receive the drug once a week through an IV. The goal is to see if the drug…

This study tests whether adding radiation before surgery to standard chemotherapy can shrink tumors more effectively in people with locally advanced breast cancer. It includes 50 participants with Luminal or triple-negative subtypes who did not respond well to initial chemo. The …

This phase 2 trial tests whether combining the targeted chemotherapy sacituzumab govitecan with the immunotherapy toripalimab works better than toripalimab plus standard chemotherapy (nab-paclitaxel) for people with advanced triple-negative breast cancer that is PD-L1 positive. A…

This early-stage trial tests whether freezing a breast tumor (cryoablation) before giving an immunotherapy drug (PD1 inhibitor) can help the immune system better recognize and attack triple-negative breast cancer. About 36 women with early-stage, high-risk breast cancer will rece…

This early-phase study will test a combination of three drugs—camrelizumab (an immunotherapy), pirfenidone (an anti-fibrotic drug), and standard chemotherapy—in 12 women with advanced triple-negative breast cancer that has already been treated with immunotherapy. The goal is to s…

This study tests a new drug called CVL006 combined with standard chemotherapy or other targeted drugs in people with advanced solid tumors that have not responded to previous treatments. The trial has two phases: first, to find the safest dose, and second, to see if the combinati…

This Phase 2 trial is testing a combination of two drugs—Sacituzumab tirumotecan and Tagitanlimab—in people with a specific type of advanced breast cancer called PD-L1-positive triple negative breast cancer. The study will enroll 47 participants whose cancer has already been trea…

This early study tests a new radioactive antibody called NTH-2403 in 16 people with advanced colorectal, head and neck, lung, or triple-negative breast cancers. The antibody targets a protein found on cancer cells and their supporting cells, allowing doctors to see tumors on scan…

This early-phase study tests a new imaging agent that targets a protein called TROP2, found on many cancer cells. About 40 adults with metastatic bladder, breast, or lung cancer will receive the agent to see where it goes in the body. The goal is to see if this tracer can help do…

This study tests whether a new MRI contrast agent, gadopiclenol, can detect brain metastases earlier than standard methods in 180 patients with advanced lung, breast, or skin cancer. Participants will receive screening brain MRIs to compare diagnosis timing and accuracy. The goal…

This study tests whether regular blood tests (ctDNA) can find triple-negative breast cancer recurrence earlier than standard follow-up. Thirty patients who had surgery for stage II or III TNBC will be randomly assigned to either standard care or standard care plus ctDNA testing e…

This study is developing a blood test called NeutroFlow that measures specific immune cells (neutrophils) to predict whether cancer patients will benefit from immunotherapy. Researchers will collect blood samples from 600 patients with several types of cancer before they start tr…

This study tests whether giving atropine before treatment can prevent diarrhea in people with advanced breast cancer receiving the drug sacituzumab govitecan. About 30 participants will receive atropine alongside their cancer therapy. The goal is to improve treatment tolerance an…

Researchers in Korea are reviewing medical records from about 2,000 patients with triple-negative breast cancer who received pembrolizumab plus chemotherapy before surgery. The study measures how many patients had no detectable cancer left in their breast and lymph nodes at surge…

This study looks at how well a chemotherapy and immunotherapy combination works for early triple-negative breast cancer when the usual anthracycline drugs are left out. The researchers are focusing on patients who cannot take anthracyclines due to previous treatment, older age, o…

This study looks at whether tracking tumor DNA in the blood (ctDNA) can help doctors see how well breast cancer treatment is working before surgery. It will include 186 people with stage II-III HER2-positive or triple-negative breast cancer. Researchers will take blood samples at…

This phase 2 trial is testing whether blood tests and imaging scans can tell if chemotherapy is working in people with early-stage triple-negative breast cancer before they go to surgery. The study will enroll 200 participants who will receive a combination of chemotherapy drugs …

This study looks at tumor samples from 55 women with early-stage breast cancer to find early signs of whether chemo-immunotherapy is working. By analyzing individual cells before, during, and after treatment, researchers hope to identify markers that predict response or resistanc…

This study aims to understand why breast cancer in young women is often more aggressive. Researchers will look at how pregnancy and breastfeeding might influence the disease. They will collect information from 1,000 women aged 45 or younger (and a comparison group aged 55+) with …

This study looks at how diet and gut bacteria affect treatment outcomes in women with early-stage triple-negative breast cancer. Researchers will collect stool, blood, and tumor samples from 300 participants before, during, and after chemotherapy and immunotherapy. The goal is to…

This study will follow 75 women aged 18-42 with early-stage triple-negative breast cancer who are receiving chemotherapy plus immunotherapy before surgery. Researchers will measure hormone levels, track menstrual patterns, and use questionnaires to see how treatment affects ovari…

This study looks back at data from 201 people with triple-negative breast cancer who received chemotherapy or immunotherapy before surgery. The goal is to compare how often the cancer completely disappears after treatment and find out what factors influence success. This is an ob…

This study will test an AI-powered tool that analyzes tumor samples to help doctors choose the best treatment for people with triple-negative breast cancer. The tool looks at immune cells in the tumor to predict how well chemotherapy might work. The goal is to see if the tool can…

This study looks at whether doing broad gene testing early, instead of later, helps find more effective treatments for people with advanced pancreatic, liver, or triple-negative breast cancer. About 360 adults with poor-prognosis cancers will be randomly assigned to early or stan…